Biointron - Antibody Discovery, Antibody Production, Stable cell line, Protein Expression, CRO

Recombinant antibody expression service — gene sequence to purified antibody in 2 weeks Antibody discovery platform — VHH single-domain and fully human antibody screening Affinity maturation optimization — CDR region site saturation mutagenesis

Services & Products

About Us

  • 0 +
    Years of Experience
  • 0 +
    Employees
  • 0 +
    Companies Served Globally
  • 0 +
    Antibodies Delivered Annually

Why you should choose us

  • Pioneering Antibody Solutions

    We specialize in antibody expression, discovery, and optimization with internationally recognized automated production standards - offering superior services at market- competitive rates with efficient turnaround times.

  • Unique Cell Line Commercialization

    We possess exclusive re-licensing rights for the commercialization of the CHO-K1BN cell line licensed from ECACC.

  • Global Collaborative Excellence

    Our partnerships with 3,000+ global biotech and pharmaceutical entities, coupled with our collaborative advancements in international clinical stages, solidify our esteemed position in the industry.

  • Trust and Exclusive Ownership

    We commit to complete confidentiality - preserving the exclusive ownership rights of the antibodies we produce for our clients.

Antibody

Engage with Biointron, your dependable partner for efficient, affordable, and top-tier custom antibody solutions.

About Biointron

Founded in 2012, and certified to ISO 9001:2015, Biointron is a CRO (Contract research organization) specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies.

Biointron is a leading high-throughput recombinant antibody/protein expression and discovery service provider. From gene sequence to purified antibodies, it just takes 2 weeks. Biointron has delivered tens of thousands of recombinant antibodies for 3,000+ biotech and pharma companies all over the world.

Read More Read More

Client Voices: Biointron Success Stories

Learn from our partners and clients about the transformative impact of Biointron's expertise.

"We evaluated the 6 proteins you produced for us and we were quite pleased by the results. our internal assessments of the molecules are very encouraging so we would like to potentially expand this further."

— AstraZeneca

"We have tested both batches of the antibodies you sent us. They're active and give comparable results with little batch to batch variation."

— AbbVie

"Excellent.The protein quality and activity was high and up to our standards, we appreciate the help and the work.The short timeline for the production is the main factor Biointron differs from other CROs."

— Moderna

"Great working with you, I've been highly impressed and recommending you to many in my network."

— Sanofi

"I just wanted to give you a quick heads-up regarding the expression we conducted at Biointron. Essentially, everything went well and was super fast, so we are all very much satisfied."

— Merck KGaA

"BioIntron was the best from the three: it was the only company that was able to express all the sequences and the yield for those proteins that the other two companies also could express was, generally, higher."

— ImmuVia, LLC

Our Latest News and Stories

Biointron Insights: Antibody Industry Trends (Q1 2026 Insights, Trends & Analysis)

Biointron’s Q1 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in January, February, and March. This quarter, three novel monoclonal antibody drugs have been approved by China.

Mar 31, 2026
Next-Generation Antibody Conjugates for Targeted Anticancer Drug Delivery

In this article, we explore the major trends shaping the future of targeted cancer drug delivery, and why integrated expertise in antibody discovery, engineering, and conjugation is becoming increasingly important for successful ADC development.

May 29, 2026
Site-Specific Conjugation Strategies for Next-Generation Antibody-Drug Conjugates

Site-specific conjugation limits payload attachment to defined positions on the antibody instead of allowing reaction across many accessible residues. As ADC design becomes more sophisticated, this level of control is increasingly important.

May 27, 2026
Biointron Launches RushData, an Integrated High-Throughput Platform for AI-Driven Antibody Discovery

Biointron, a leading contract research organization specializing in antibody discovery, expression, and optimization for global biotechnology and pharmaceutical companies, today announced the launch of RushData, a new integrated service platform designed to support the growing demands of AI- and machine learning-driven antibody discovery.

Jun 16, 2026
Biointron Launches RushMab™ Packages to Deliver Purified Antibodies in 10 Days

Biointron, a contract research organization specializing in antibody discovery and production services with offices located in Cambridge, Massachusetts, and Piscataway, New Jersey, has released Small-Scale Antibody Expression Packages under the RushMab brand, compressing the wait to as few as 4 days for transfection-grade expression plasmids and 10 days for purified, quality-controlled antibody material.

May 29, 2026
Biointron Launches Comprehensive Antibody Developability Assessment Platform to Accelerate Biologic Drug Discovery

Biointron launched its Antibody Developability Assessment Services to help drug developers catch potential problems before they turn into expensive failures. The platform combines high-throughput antibody production with a full panel of tests that check whether candidates can be manufactured at scale and remain stable throughout their shelf life, with results delivered in three to five days per assay.

Apr 15, 2026
Immunology 2026

Time: April 15 - 19, 2026
Location: Boston, MA
Booth: #1228

BIO Korea 2026

Time: April 28 – 30, 2026
Location: Seoul, South Korea
Booth: #B31

CHABS 2026 Annual Conference

Time: May 9 - 10, 2026
Location: Boston, MA

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.